DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction

Journal of Virology

Volumn 71, Issue 11, 1997, Pages 8497-8503

  Rodriguez, Fernando ^a   Zhang, Jie ^a   Whitton, J Lindsay ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UBIQUITIN; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN PROCESSING; VERO CELL; VIRUS IMMUNITY; VIRUS TITRATION;

EID: 0030812840     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.11.8497-8503.1997     Document Type: Article

References (41)

1. Aichele, P., H. Hengartner, R. M. Zinkernagel, and M. Schulz. 1990. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171:1815-1820.
2. Argiles, J. M., and F. J. Lopez-Soriano. 1996. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol. Sci. 17:223-226.
3. Cerundolo, V., A. Benham, V. Brand, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur. J. Immunol. 27:336-341.
4. Corr, M., D. J. Lee, D. A. Carson, and H. Tighe. 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184:1555-1560.
5. Cox, J. H., P. Galardy, J. R. Bennink, and J. W. Yewdell. 1995. Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J. Immunol. 154:511-519.
6. Ecker, D. J., J. M. Stadel, T. R. Butt, J. A. Marsh, B. P. Monia, D. A. Powers, J. A. Gorman, P. E. Clark, F. Warren, and A. Shatzman. 1989. Increasing gene expression in yeast by fusion to ubiquitin. J. Biol. Chem. 264:7715-7719.
7. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731.
8. Finch, J. S., K. Bonham, P. Krieg, and G. T. Bowden. 1990. Murine polyubiquitin mRNA sequence. Nucleic Acids Res. 18:1907.
9. Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson. 1995. DNA vaccines: a novel approach to immunization. Int. J. Immunopharmacol. 17:79-83.
10. Hany, M., S. Oehen, M. Schulz, H. Hengartner, M. Mackett, D. H. L. Bishop, H. Overton, and R. M. Zinkernagel. 1989. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur. J. Immunol. 19:417-424.
11. Hassett, D. E., and J. L. Whitton. 1996. DNA immunization. Trends Microbiol. 4:307-312.
12. Hochstrasser, M. 1995. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol. 7:215-223.
13. Iwasaki, A., C. A. T. Torres, P. S. Ohashi, H. L. Robinson, and B. H. Barber. 1997. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159:11-14.
14. Klavinskis, L. S., M. B. A. Oldstone, and J. L. Whitton. 1989. Designing vaccines to induce cytotoxic T lymphocytes: protection from lethal viral infection, p. 485-489. In F. Brown, R. Chanock, H. Ginsberg, and R. Lerner (ed.), Vaccines 89. Modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
15. Klavinskis, L. S., J. L. Whitton, and M. B. A. Oldstone. 1989. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63:4311-4316.
16. Kozak, M. 1987. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15:8125-8148.
17. Kulkarni, A. B., P. L. Collins, I. Bacik, J. W. Yewdell, J. R. Bennink, J. E. Crowe, and B. R. Murphy. 1995. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol. 69:1261-1264.
18. Lehner, P. J., and P. Cresswell. 1996. Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol. 8:59-67.
19. Liu, M. A., M. R. Hilleman, and R. Kurth (ed.). 1995. DNA vaccines: a new era in vaccinology. New York Academy of Sciences, New York, N.Y.
20. Michalek, M. T., E. P. Grant, C. Gramm, A. L. Goldberg, and K. L. Rock. 1993. A role for the ubiquitin-dependent proteolytic pathway in MHC class I restricted antigen presentation. Nature 363:552-554.
21. Michalek, M. T., E. P. Grant, and K. L. Rock. 1996. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. J. Immunol. 157:617-624.
22. 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature 368:864-867.
23. Pedroza Martins, L., L. L. Lau, M. S. Asano, and R. Ahmed. 1995. DNA vaccination against persistent viral infection. J. Virol. 69:2574-2582.
24. Price, S. R., J. L. Bailey, X. Wang, C. Jurkovitz, B. K. England, X. Ding, L. S. Phillips, and W. E. Mitch. 1996. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J. Clin. Invest. 98: 1703-1708.
25. Rock, K. L. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131-137.
26. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771.
27. Schulz, M., P. Aichele, M. Vollenweider, F. W. Bobe, F. Cardinaux, H. Hengartner, and R. M. Zinkernagel. 1989. Major histocompatibility complex-dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur. J. Immunol. 19:1657-1668.
28. Shean, B. S., and D. L. Mykles. 1995. Polyubiquitin in crustacean striated muscle: increased expression and conjugation during molt-induced claw muscle atrophy. Biochim. Biophys. Acta 1264:312-322.
29. Solomon, V., and A. L. Goldberg. 1996. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J. Biol. Chem. 271:26690-26697.
30. Tiao, G., S. Hobler, J. J. Wang, T. A. Meyer, F. A. Luchette, J. E. Fischer, and P. O. Hasselgren. 1997. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Invest. 99:163-168.
31. Tobery, T. W., and R. F. Siliciano. 1997. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185:909-920.
32. Townsend, A. R. M., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar, D. Boyle, S. Chan, and G. Smith. 1988. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168:1211-1224.
33. Varshavsky, A. 1996. The N-end rule: functions, mysteries, uses. Proc. Natl. Acad. Sci. USA 93:12142-12149.
34. Whalen, R. G., and H. L. Davis. 1995. DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin. Immunol. Immunopathol. 75:1-12.
35. Whitton, J. L. 1990. Lymphocytic choriomeningitis virus CTL. Semin. Virol. 1:257-262.
36. Whitton, J. L., J. R. Gebhard, H. Lewicki, A. Tishon, and M. B. A. Oldstone. 1988. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeninigitis virus. J. Virol. 62:687-695.
37. Whitton, J. L., and M. Yokoyama. 1996. Proteins expressed by DNA vaccines induce both local and systemic immune responses. Ann. N. Y. Acad. Sci. 797:196-206.
38. Whitton, J. L., and J. Zhang. 1995. Principles of CTL induction and recognition. Curr. Top. Microbiol. Immunol. 202:247-259.
39. Yokoyama, M., J. Zhang, and J. L. Whitton. 1995. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. 69:2684-2688.
40. Yokoyama, M., J. Zhang, and J. L. Whitton. 1996. DNA immunization: effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol. Med. Microbiol. 14:221-230.
41. Zarozinski, C. C., E. F. Fynan, L. K. Selin, H. L. Robinson, and R. M. Welsh. 1995. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J. Immunol. 154:4010-4017.